Abstract 1628P
Background
Advanced gastrointestinal (GI) tumors, such as colorectal, gastric and pancreatic cancers (CRC, GC and PC), and esophageal squamous cell carcinoma (ESCC), 20%-50% with liver metastases (LMs) and have poor prognosis. Previous trials showed anlotinib plus chemotherapy (CT) has promising clinical activity and a tolerable safety profile for advanced CRC and ESCC, especially with LMs. In this phase II trial, we assessed the efficacy and safety of anlotinib plus CT as first-line (1L) treatment for LMs GI tumors.
Methods
Previous untreated pts with unresectable LMs GI tumors received induction therapy (6 cycles, q3w) in 3 cohorts: cohort A (CRC): anlotinib (12 mg, po, qd, d1-d14), oxaliplatin (130 mg/m2, iv, d1), capecitabine (850 mg/m2, po, bid, d1-14). B (ESCC): anlotinib, cisplatin (60-750 mg/m2, iv, d1/d1-3), paclitaxel (135 mg/m2, iv, d1) or docetaxel (75 mg/m2, iv, d1). C (other GI tumors, e.g., PC, GC): anlotinib plus standard CT. Pts without PD and radical resection received anlotinib and metronomic capecitabine (500 mg, po, bid, d1-21, q3w) maintenance until PD or unacceptable toxicity. The primary endpoint was ORR (RECIST 1.1). Secondary endpoints were DoR, PFS, OS, DCR, radical resection rate for LMs and safety.
Results
As of May 8th, 2023, 74 pts were enrolled, 33 in cohort A, 3 in B and 38 in C (26 PC, 6 GC, 5 biliary tract cancer (BTC) and others), median age was 64 years (34-75), 70.3% male, 91.9% ECOG-PS 1 and 59.5% had LMs only. After induction therapy, 8 pts (5 CRC, 1 PC, 1 GC, 1 BTC) received surgical resection. Of 19 evaluable pts in cohort A, ORR and DCR were 57.9% and 100% (PR, n=11; SD, n=8, 5 SD had reduced tumor size). All 3 pts in cohort B were PR. Of 28 evaluable pts in cohort C, ORR and DCR were 39.3% and 85.7% (PR, n=11; SD, n=13, 6 SD had reduced tumor size). Of 16 evaluable PC pts, 7 had PR, 7 had SD, ORR 43.8%. The mPFS was not reached. 50 pts had TEAEs and grade 3/4 TEAEs (28.4%) mainly included neutropenia (13.5%), hypertension (6.8%) and white blood cell decreased (5.4%).
Conclusions
Anlotinib plus chemotherapy as 1L treatment has shown promising efficacy and acceptable safety and may be a favorable option for advanced LMs GI tumors, especially for PC.
Clinical trial identification
NCT05262335.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1635P - Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic ductal adenocarcinoma patients
Presenter: Giulia Orsi
Session: Poster session 22
1636P - Circulating tumor DNA (ctDNA) profile in patients (pts) with pancreatic cancer (PC): A multicenter experience and challenges for clinical application
Presenter: Francisco Muñoz i Carrillo
Session: Poster session 22
1637P - Early retention of KRAS mutations in cfDNA is an ominous sign for pancreatic cancer patients during chemotherapy: A prospective cohort study
Presenter: Chien-Jui Huang
Session: Poster session 22
1638P - The prognostic and predictive role of class III β-tubulin and hENT1 expression in patients with advanced pancreatic ductal adenocarcinoma
Presenter: Taha Koray Sahin
Session: Poster session 22
1639P - Feasibility of tumor genomic sequencing on tissue obtained from endoscopic ultrasound in patients with pancreatic cancer
Presenter: Vaia Florou
Session: Poster session 22
1640P - Response monitoring with ctDNA in metastatic pancreatic cancer
Presenter: Jinwoo Ahn
Session: Poster session 22
1642P - Prognostic impact of an immunomorphological signature integrating immune, fibroblastic and tumor markers in a series of 217 resected pancreatic adenocarcinoma patients
Presenter: Franck MONNIEN
Session: Poster session 22
1643P - Clinical outcomes of FOLFIRINOX as front-line therapy in patients with localized pancreatic adenocarcinoma: Asian retrospective study of 781 patients
Presenter: Kyunghye Bang
Session: Poster session 22
1644P - The mutation landscape and evolution pattern of liver or peritoneal metastasis in pancreatic cancer
Presenter: Guoliang Yao
Session: Poster session 22